Our Commitment to Patients
With patients at the core of everything we do, we are continuously seeking ways to improve the treatment paradigm for patients with seizure disorders.
Our dedicated team of professionals, scientists, and medical experts strive to demonstrate the value of ganaxolone as a potential first-in-class, fast-acting, safe, and innovative therapy for children and adults afflicted with seizure disorders.
Patient resources and clinical trial information
Information about Marinus’ clinical trials can be found on ClinicalTrials.gov.
Status Epilepticus (SE)
Status epilepticus is the occurrence of an epileptic seizure of a prolonged duration of more than five minutes or several seizures within a five-minute period where the individual does not recover between seizures.
CDKL5 Deficiency Disorder (CDD)
CDKL5 deficiency disorder (CDD) is a serious and rare genetic disorder that is caused by a mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome.
Tuberous Sclerosis Complex (TSC)
Tuberous sclerosis complex (TSC) is a rare genetic disorder that affects many organs and causes non-malignant tumors in the brain, skin, kidney, heart, eyes, and lungs.
Collaboration
We collaborate with patient advocacy organizations to increase awareness and education, promote earlier diagnosis, advance new therapies, better understand the patients we serve, and improve quality of care. Together, we hope to make a difference.
If you are a patient advocacy organization interested in collaborating with us, please email patientadvocacy@marinuspharma.com.